aDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
bCutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
cNovartis Pharmaceuticals Corporation, East Hanover, New Jersey
dAsclepius Analytics Ltd., New York, New York, USA
Received 26 April 2022 Accepted 4 August 2022
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.melanomaresearch.com.
Correspondence to You-Li Ling, PhD, Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, USA, E-mail: [email protected]